Recent studies have converged on the intersection of GLP|GIP|GCGR agonist therapies and dopamine signaling. While GIP activators are commonly employed for addressing type 2 diabetes mellitus, their emerging consequences on reward circuits, specifically mediated by dopamine systems, are gaining substantial interest. This report details a summary … Read More